Under a tenth of people who could benefit from GLP-1 drugs including Wegovy are able to get them, states the global health agency as it releases its inaugural advice on the drugs.
With in excess of 1,000,000,000 people worldwide now obese, it is advocating for more widespread and fairer access to these injectable treatments.
Per projections, more than two billion could be living with obesity by 2030 without intervention.
"The latest guidance affirms that obesity is a long-term condition that can be managed with thorough and ongoing treatment," said its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are key hurdles to broad availability to the treatments that can aid individuals in losing substantial body mass, notes the body.
Skinny Jab Scarcity
Even under the present best projected scenario, the production of GLP-1 therapies could only cover about 100 million people – fewer than 10% of the global need, as stated by the health organization.
The advice encourages governments and firms to increase availability, by approaches such as patent sharing.
Exclusive production rights on a key compound – the main ingredient of a leading brand – is scheduled to end in multiple nations in 2026.
The Way Weight-Loss Injections Operate
The injections mimick a body's own hormone to reduce digestion speed, suppress the appetite and enhance satiety so people reduce food intake.
People commonly see weight reduction within a few weeks of beginning the regular doses.
Studies points to people may put most of the weight back on within a year of halting the medication, when their typical appetite resume.
To be carrying excess weight increases your chance for contracting diseases, like diabetes, heart disease, stroke, and specific cancers.
Excess weight affects individuals in every country and was associated with over three and a half million deaths worldwide in 2024, according to the WHO.
